AZ, MZ, and the Pulmonary System Response to Hypoxia

Overseen by Glen E Foster, Ph.D.

Age: 18 - 65

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: University of British Columbia

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this proposal is to compare the physiological effects of acetazolamide (AZ) and methazolamide (MZ) on the control of breathing and hypoxic pulmonary vasoconstriction. The first objective is to assess the effects of AZ and MZ on the control of breathing in normoxia and hypoxia. To achieve this the ventilatory interaction between oxygen and carbon dioxide will be measured and effects compared between placebo, AZ, and MZ conditions. In addition, the isocapnic and poikilocapnic hypoxic ventilatory response and hypercapnic ventilatory response will be measured with each drug. The second objective is to assess the effects of AZ and MZ on the control of the pulmonary vasculature during hypoxia. Pulmonary pressure and cardiac output will be measured during 60 minutes of poikilocapnic hypoxia.

Research Team

Glen E Foster, Ph.D.

Principal Investigator

University of British Columbia

Eligibility Criteria

Inclusion Criteria

18-40 years of age

regularly physically active

male

Treatment Details

Interventions

• Acetazolamide (Carbonic Anhydrase Inhibitor)
• Methazolamide (Carbonic Anhydrase Inhibitor)
• Placebo (Drug)

Participant Groups

Group I: Methazolamide Experimental Treatment 1 Intervention

Participants will be dosed 100mg Methazolamide (p.o.) twice daily separated by a placebo for two days prior to and a single dose on the day of study. The placebo dose is provided to match the dosing schedule between conditions.

Group II: Acetazolamide Experimental Treatment 1 Intervention

Participants will be dosed 250mg Acetazolamide (p.o.) three times per day for two days prior to and a single dose on the day of study.

Group III: Placebo Placebo Group 1 Intervention

Participants will take (p.o.) placebo pills three times per day for two days prior to and a single dose on the day of study.

Acetazolamide is already approved in Canada for the following indications:

Approved in Canada as Diamox for:

• Glaucoma
• Epilepsy
• Edema
• Altitude sickness

Who Is Running the Clinical Trial?

University of British Columbia

Lead Sponsor

Trials

1,506

Recruited

2,528,000+

Dr. Christopher Haqq

University of British Columbia

Chief Medical Officer since 2019

MD, University of British Columbia

Bekki Bracken Brown

University of British Columbia

Chief Executive Officer since 2023

Bachelor's degree from Duke University